Current morphological diagnosis of malignant lung tumors
作者： K. Junker
DOI: 10.1007/S00292-006-0818-1
关键词:
摘要: The histological classification of lung tumors is based upon the 2004 WHO classification. Small cell cancer (SCLC) primarily treated by means anti-neoplastic chemotherapy, independently tumor stage. In resectable stages non-small (NSCLC, UICC-stages I and II), complete resection aim. Therefore, distinction between SCLC NSCLC still particular importance. Currently, great interest focused on identification specific therapeutic targets, especially inhibition epidermal growth factor ruptur (EGFR). Today, malignant can also be classified molecular pathology. Subgroups with different prognoses identified gene expression profiling. levels several genes are associated sensitivity against certain anti-cancer agents.
springer.com
sci-hub.se 参考文章(23)
K. Junker, Therapieinduzierte morphologische Veränderungen bösartiger Lungentumoren Pathologe. ,vol. 25, pp. 475- 480 ,(2004) , 10.1007/S00292-004-0719-0
Juanita Hatcher, Douglas C. Dover, Trends in histopathology of lung cancer in Alberta. Canadian Journal of Public Health-revue Canadienne De Sante Publique. ,vol. 94, pp. 292- 296 ,(2003) , 10.17269/CJPH.94.343
LH Sobin, WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, Histological Typing of Lung and Pleural Tumours ,(1999)
B. Corrin, Andrew G. Nicholson, Pathology of the Lungs ,(1999)
Shuta Tomida, Katsumi Koshikawa, Yasushi Yatabe, Tomoko Harano, Nobuhiko Ogura, Tetsuya Mitsudomi, Masato Some, Kiyoshi Yanagisawa, Toshitada Takahashi, Hirotaka Osada, Takashi Takahashi, Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients Oncogene. ,vol. 23, pp. 5360- 5370 ,(2004) , 10.1038/SJ.ONC.1207697
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
M. E. Garber, O. G. Troyanskaya, K. Schluens, S. Petersen, Z. Thaesler, M. Pacyna-Gengelbach, M. van de Rijn, G. D. Rosen, C. M. Perou, R. I. Whyte, R. B. Altman, P. O. Brown, D. Botstein, I. Petersen, Diversity of gene expression in adenocarcinoma of the lung Proceedings of the National Academy of Sciences of the United States of America. ,vol. 98, pp. 13784- 13789 ,(2001) , 10.1073/PNAS.241500798
Thomas J. Giordano, Kerby A. Shedden, Donald R. Schwartz, Rork Kuick, Jeremy M.G. Taylor, Nana Lee, David E. Misek, Joel K. Greenson, Sharon L.R. Kardia, David G. Beer, Gad Rennert, Kathleen R. Cho, Stephen B. Gruber, Eric R. Fearon, Samir Hanash, Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles American Journal of Pathology. ,vol. 159, pp. 1231- 1238 ,(2001) , 10.1016/S0002-9440(10)62509-6
K. Junker, T. Wiethege, K.-M. Müller, M. Thomas, p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy. Journal of Cancer Research and Clinical Oncology. ,vol. 126, pp. 238- 245 ,(2000) , 10.1007/S004320050039
K. Junker, Th. Wiethege, K.-M. Müller, Pathology of small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. ,vol. 126, pp. 361- 368 ,(2000) , 10.1007/PL00008483